The fact that our panel includes prognostically relevant genes (NRAS, KRAS, TP53, BRAF) as well as potentially actionable targets or pathways (RAS, TP53, BRAF, CCND1, IRF4) also renders our approach a useful tool for improving prognostication and treatment in plasma cell disorders.17, 18, 19, 20, 21, 22, 23 The complex genomic architecture evident in our data set, however, highlights the need for therapeutic strategies directed at multiple targets rather than at a single genomic anomaly and underscores the success of combination therapies. This evidence concerns the gene KRAS and plasma cell neoplasm.